Brain

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Staff December 18, 2023

Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX /...

IRLAB Submits Request for an End-of-Phase 2 Meeting with the FDA for the Phase III-ready Mesdopetam Program

Staff December 18, 2023

GOTHENBURG, SE / ACCESSWIRE / December 18, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 18, 2023 - IRLAB...

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update

Staff December 15, 2023

EDEN PRAIRIE, Minn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a...

Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL

Staff December 14, 2023

Topline Data from a Registration-Enabling Phase 3 Clinical Trial is Due Later This Month.CHATHAM, NJ / ACCESSWIRE / December 14,...

ModMed Boosts Its Communication Efficiency With Grammarly’s AI Writing Assistance

Staff December 14, 2023

Grammarly’s comprehensive writing assistance with generative AI features drives 28x ROI and saves over 19 working days per year per...

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years

Staff December 14, 2023

At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence...

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Staff December 14, 2023

Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy...

Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.

Staff December 12, 2023

LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. (OTCOB:ODYY), a company focused on developing unique,...

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

Staff December 12, 2023

Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and...

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

Staff December 12, 2023

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug...

IRLAB is Granted Additional Patent for Drug Candidate Pirepemat that Expands its Patent Protection

Staff December 12, 2023

GOTHENBURG, SE / ACCESSWIRE / December 12, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 12, 2023 - IRLAB...

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

Staff December 11, 2023

Glen Rock, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”),...

Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions

Staff December 11, 2023

VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing...

Angle PLC Announces Parsortix Unlocks Opportunities for Drug Discovery

Staff December 11, 2023

USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERYHarvested CTCs reveal gene expression profile associated with development...

Unlocking the Fountain of Longevity: Longevity Investors Lunch Returns to Davos During WEF, Where Innovation Meets Investment in the Pursuit of Timeless Opportunities

Staff December 8, 2023

Zug, Switzerland--(Newsfile Corp. - December 8, 2023) - Longevity Investors Lunch returns for the third edition during the 2024 World...

Milestone Scientific Commences Sales of CompuFlo® Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures

Staff December 8, 2023

Adoption of the technology at UTMB Health Clear Lake Campus Hospital follows successful evaluation process in these procedures—reporting 100% success...

Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers

Staff December 7, 2023

CHICAGO, IL / ACCESSWIRE / December 7, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...

AlzeCure Presents at Redeye Investor Forum in Göteborg on December 14

Staff December 7, 2023

STOCKHOLM, SE / ACCESSWIRE / December 07, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Staff December 6, 2023

HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is...

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Staff December 6, 2023

HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is...

Brain

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

IRLAB Submits Request for an End-of-Phase 2 Meeting with the FDA for the Phase III-ready Mesdopetam Program

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update

Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL

ModMed Boosts Its Communication Efficiency With Grammarly’s AI Writing Assistance

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

IRLAB is Granted Additional Patent for Drug Candidate Pirepemat that Expands its Patent Protection

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions

Angle PLC Announces Parsortix Unlocks Opportunities for Drug Discovery

Unlocking the Fountain of Longevity: Longevity Investors Lunch Returns to Davos During WEF, Where Innovation Meets Investment in the Pursuit of Timeless Opportunities

Milestone Scientific Commences Sales of CompuFlo® Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures

Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers

AlzeCure Presents at Redeye Investor Forum in Göteborg on December 14

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity

Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

You may have missed